BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12015701)

  • 21. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
    Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
    J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Older age and the response to and tolerability of antiretroviral therapy.
    Silverberg MJ; Leyden W; Horberg MA; DeLorenze GN; Klein D; Quesenberry CP
    Arch Intern Med; 2007 Apr; 167(7):684-91. PubMed ID: 17420427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
    Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
    Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspective on HIV infection and aging: emerging research on the horizon.
    Casau NC
    Clin Infect Dis; 2005 Sep; 41(6):855-63. PubMed ID: 16107986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of prolonged HAART on oral colonization with Candida and candidiasis.
    Yang YL; Lo HJ; Hung CC; Li Y
    BMC Infect Dis; 2006 Jan; 6():8. PubMed ID: 16423306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
    Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
    Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort.
    Collini P; Schwab U; Sarfo S; Obeng-Baah J; Norman B; Chadwick D; Bibby D; Bedu-Addo G
    Clin Infect Dis; 2009 Apr; 48(7):988-91. PubMed ID: 19231976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-infected patients with a large thymus maintain higher CD4 counts in a 5-year follow-up study of patients treated with highly active antiretroviral therapy.
    Kolte L; Ryder LP; Albrecht-Beste E; Jensen FK; Nielsen SD
    Scand J Immunol; 2009 Dec; 70(6):608-13. PubMed ID: 19906203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy.
    Santin M; Alcaide F
    Int J Tuberc Lung Dis; 2003 Jul; 7(7):673-7. PubMed ID: 12870689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.
    Stock PG; Roland ME; Carlson L; Freise CE; Roberts JP; Hirose R; Terrault NA; Frassetto LA; Palefsky JM; Tomlanovich SJ; Ascher NL
    Transplantation; 2003 Jul; 76(2):370-5. PubMed ID: 12883195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression.
    Dronda F; Moreno S; Moreno A; Casado JL; Pérez-Elías MJ; Antela A
    Clin Infect Dis; 2002 Oct; 35(8):1005-9. PubMed ID: 12355389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.